Fondaparinux contraindications: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) |
No edit summary |
||
| Line 7: | Line 7: | ||
ARIXTRA is contraindicated in the following conditions: | ARIXTRA is contraindicated in the following conditions: | ||
*Severe [[renal impairment]] ( [[creatinine clearance]] [CrCl] < 30 mL/min). [See [[Fondaparinux warnings and precautions|Warnings and Precautions]] and[[ Fondaparinux use in specific populations| Use in Specific Populations ]]] | |||
*Active major [[bleeding]]. | |||
*Bacterial [[endocarditis]]. | |||
*[[Thrombocytopenia]] associated with a positive in vitro test for anti-platelet antibody in the presence of fondaparinux sodium. | |||
*Body weight < 50 kg ( [[venous thromboembolism]] [[[VTE]]] prophylaxis only) [see [[Fondaparinux warnings and precautions|Warnings and Precautions]] ]. | |||
*History of serious [[hypersensitivity]] reaction (e.g., [[angioedema]], [[anaphylactoid]]/[[anaphylactic]] reactions) to ARIXTRA.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ARIXTRA (FONDAPARINUX SODIUM) INJECTION, SOLUTION [GLAXOSMITHKLINE LLC] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=05bb2dd4-5fb5-4ec9-29a8-d200e62d1a8f | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Revision as of 20:29, 3 March 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Contraindications
ARIXTRA is contraindicated in the following conditions:
- Severe renal impairment ( creatinine clearance [CrCl] < 30 mL/min). [See Warnings and Precautions and Use in Specific Populations ]
- Active major bleeding.
- Bacterial endocarditis.
- Thrombocytopenia associated with a positive in vitro test for anti-platelet antibody in the presence of fondaparinux sodium.
- Body weight < 50 kg ( venous thromboembolism [[[VTE]]] prophylaxis only) [see Warnings and Precautions ].
- History of serious hypersensitivity reaction (e.g., angioedema, anaphylactoid/anaphylactic reactions) to ARIXTRA.[1]
References
Adapted from the FDA Package Insert.